Another RIPK1 inhibitor DNL747 is currently in clinical development for the treatment of neurodegenerative diseases including Amyotrophic lateral sclerosis (NCT03757351) and Alzheimer’s disease (NCT03757325) (Table 3). Here, RIPK1 is linked to amyotrophic lateral sclerosis.